Novel COPD Exercise Claims Eluded Boehringer In Bid to Differentiate Striverdi
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsor’s claimed impact on exercise tolerance was not adequately supported and should not serve as a marketing advantage for the chronic obstructive pulmonary disease drug, FDA review staff said. However, Boehringer Ingelheim’s failed attempt for the exercise-related labeling language spurred the agency to clarify the types of studies and endpoints that potentially could support such claims.
You may also be interested in...
Keeping Track: Approvals For Addyi, Adcetris; Merck Bulks Up Keytruda Filings
The latest drug development news and highlights from our FDA Performance Tracker.
Manufacturing Updates in Brief
GMP issues delayed Boehringer launch; Nigerian firms meet WHO GMPs; Novartis closing Puerto Rico plant; Hospira closing Clayton site; Valeant looks to move Bausch + Lomb manufacturing abroad; these IV bags were training aides.
Manufacturing Updates in Brief
GMP issues delayed Boehringer launch; Nigerian firms meet WHO GMPs; Novartis closing Puerto Rico plant; Hospira closing Clayton site; Valeant looks to move Bausch + Lomb manufacturing abroad; these IV bags were training aides.